Madrigal

Madrigal Pharmaceuticals (MDGL)

Company Description

Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease.

COMPANY ADDRESS
200 Barr Harbor Drive, Suite 400
West Conshohocken, PA 19428
United States

COMPANY EMAIL
info@madrigalpharma.com

COMPANY WEBSITE



Get BioInvest's perspective on Madrigal Pharmaceutical's CEO


Latest Company News

Madrigal Pharmaceuticals, Inc. (NasdaqCM:MDGL) Placed in the Hotbed: What Are ... Financial Newsweek - 2 hours ago The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Madrigal Pharmaceuticals, Inc. NasdaqCM:MDGL is 3.166959. A lower price to book ratio indicates that the stock might be ... [...]
Sat, Aug 19, 2017 2:26:00 AM, Continue reading at the source
Price Alert: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Stock Nears Resistance ... CML News - 9 hours ago Price Alert: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has now crossed into technical strength -- watch the technical oscillators for momentum gaps. [...]
Fri, Aug 18, 2017 7:52:00 PM, Continue reading at the source
Decision Time: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Stock Technicals Hit ... CML News - Aug 10, 2017 Decision Time: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) now sits in the perhaps the most difficult technical position -- the stock has no urgency in its direction and that has left it at an inflection point. [...]
Thu, Aug 10, 2017 7:41:00 PM, Continue reading at the source
Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept ... Nasdaq - Aug 1, 2017 CONSHOHOCKEN, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that it has completed patient enrollment of 125 patients, exceeding its targeted enrollment of 117 patients, in its Phase 2 ... [...]
Tue, Aug 01, 2017 11:26:00 AM, Continue reading at the source
Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results GlobeNewswire (press release) - May 11, 2017 CONSHOHOCKEN, Pa., May 11, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2017 financial results. [...]
Thu, May 11, 2017 9:00:00 PM, Continue reading at the source
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License ... GlobeNewswire (press release) - Sep 19, 2016 CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the ... With $163M Deal, Tarveda Revives Synta Pharma's Cancer Drug Work - Xconomy [...]
Mon, Sep 19, 2016 11:31:00 AM, Continue reading at the source
Synta - Madrigal Merger: Is There A Potential Value Play Here? Seeking Alpha - Aug 23, 2016 On April 13, 2016 Synta and Madrigal Pharmaceuticals (NASDAQ:MDGL) entered into an arrangement and plan of merger pursuant to which Saffron Merger Sub Inc., a wholly owned subsidiary of Synta, will merge into MDGL, with Madrigal surviving as the ... [...]
Tue, Aug 23, 2016 11:48:00 PM, Continue reading at the source
15.92 MarketWatch - Jul 25, 2016 Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. [...]
Mon, Jul 25, 2016 8:03:00 PM, Continue reading at the source
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading ... GlobeNewswire (press release) - Jul 22, 2016 FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ... [...]
Fri, Jul 22, 2016 3:22:00 PM, Continue reading at the source
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals Zacks.com - Apr 15, 2016 This all-stock transaction will lead to the formation of a new company named Madrigal Pharmaceuticals, which will focus on the development of novel small-molecule drugs addressing major unmet needs related to cardiovascular-metabolic diseases and ... Ganetespib efforts muted; Synta 'Bach' in play via merger with Madrigal ... - BioWorld Online Synta Pharma and Madrigal Pharma to merge in all-stock deal - Seeking Alpha [...]
Fri, Apr 15, 2016 2:47:00 PM, Continue reading at the source